Clinical trial · Interventional
A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer
NCT01784107CI-TRIAL-00020850unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase 1 : To evaluate MTD(Maximal tolerated dose)and DLT(Dose limiting Toxicity) of Belotecan and Ifosfamide. Phase 2 : To analyse efficacy and toxicity of Belotecan and Ifosfamide.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Belotecan and Ifosfamide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Belotecan and Ifosfamide
- interventionNames
- Drug: Belotecan and Ifosfamide
Primary outcomes (1)
- measure
- MTD (maximal tolerated dose)
- timeFrame
- one year
Secondary outcomes (1)
- measure
- DLT(dose-limiting toxicity)
- timeFrame
- one year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically or cytologically confirmed extensive disease of Small cell lung cancer * no prior chemotherapy or radiotherapy for lung * measurable lesion for RECIST * over 18 years * ECOG 0\~2 * expected life span more than 3 months Exclusion Criteria: * acute or active infection * uncontrolled cerebral nerve symptoms or metastasis * significant myocardial infarction or cardiac disease within 12 months
References
Publications (0)
Data not yet available
No reference posted for this study.